REGENERON PHARMAC.DL-,001
REGENERON PHARMAC.DL-,001/ US75886F1075 /
RGO
|
23.12.2024 12:22:35
|
Zm.
+2,200
|
Wolumen |
Bid12:42:22 |
Ask12:42:22 |
Kapitalizacja Rynkowa |
St. dywidendy |
Wskaźnik C/Z |
|
679,000EUR
|
+0,33%
|
17
Obrót: 11 456,200 |
672,800Wolumen Bid: 15 |
679,200Wolumen Ask: 15 |
73,96 mldEUR |
- |
- |
Opis działalności
Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for high LDL cholesterol, eye diseases, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, atopic dermatitis, pain, and infectious diseases.
Zarząd & Rada nadzorcza
| CEO |
| Dr. Leonard S. Schleifer |
| Zarząd |
| Robert E. Landry, Dr. George D. Yancopoulos |
| Rada nadzorcza |
| Arthur F. Ryan, Christine A. Poon, Craig B. Thompson, Dr. Bonnie L. Bassler, Dr. George D. Yancopoulos, Dr. Leonard S. Schleifer, Dr. Marc Tessier-Lavigne, George L. Sing, Huda Y. Zoghbi, M.D., Joseph L. Goldstein, M.D., Michael S. Brown, M.D., Tony Coles, M.D. |
Dane firmy
| Nazwa: |
Regeneron Pharmaceuticals Inc. |
| Adres: |
777 Old Saw Mill River Road,Tarrytown, New York 10591-6707, USA |
| Telefon: |
+1-914-847-7000 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
is.gd/sEAmh8 |
| Przemysł: |
Biotechnologia |
| Sektor: |
Biotechnologia |
| Podsektor: |
Biotechnologia |
| Koniec roku finansowego: |
31.12 |
| Free float: |
68,40% |
| Data IPO: |
12.04.1991 |
Główni akcjonariusze
| Inne |
|
50,26% |
| FMR LLC. |
|
9,52% |
| Vanguard Group |
|
8,16% |
| BlackRock Inc. |
|
7,96% |
| JP Morgan Chase & Co. |
|
6,67% |
| Capital World Investors |
|
4,73% |
| State Street Corporation |
|
4,52% |
| Capital International Investors |
|
2,69% |
| Dodge & Cox |
|
2,18% |
| Inne |
|
3,30% |
